377 results on '"Zangari M"'
Search Results
2. Not all PBILs are the same: Unveiling the different learning mechanisms of PBIL variants
3. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
4. Clinical value of molecular subtyping multiple myeloma using gene expression profiling
5. Inhibiting MEK in MAPK pathway-activated myeloma
6. Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss
7. The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma
8. Impact of a change in antibacterial prophylaxis on bacteremia and hospitalization rates following outpatient autologous peripheral blood stem cell transplantation for multiple myeloma
9. VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
10. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
11. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
12. Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation
13. Use of quantitative ultrasound of the hand phalanges in the diagnosis of two different osteoporotic syndromes: Cushing’s syndrome and postmenopausal osteoporosis
14. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
15. Transplantation as salvage therapy for high-risk patients with myeloma in relapse
16. Recovery of Bone Mineral Density after Surgical Cure, but not by Ketoconazole Treatment, in Cushing’s Syndrome
17. Predictive value of left ventricular ejection fraction in stem cell transplantation
18. Different rates of forearm bone loss in healthy women with early or late menopause
19. 2. Multiple Myleoma: 011 TOTAL THERAPIES (TT) 1, 2, 3 FOR MULTIPLE MYELOMA (MM): THE ARKANSAS EXPERIENCE WITH 1000 PATIENTS
20. Clinical activity of arsenic trioxide for the treatment of multiple myeloma
21. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
22. PS1386 CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA
23. PF606 ADVERSE IMPACT OF PRIOR THERAPY ON TRANSPLANT OUTCOME IN MULTIPLE MYELOMA
24. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
25. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
26. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
27. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
28. Erratum: Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
29. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
30. Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)
31. Impact of bortezomib on bone health in myeloma: A review of current evidence
32. Americana. Storie e culture degli Stati Uniti dalla A alla Z
33. Clinical value of molecular subtyping multiple myeloma using gene expression profiling
34. Surgical Control/Cure of 5TGM1 Murine Multiple Myeloma Model by Thyroparathyroidectomy
35. Jumping Translocations of 1q12 in Multiple Myeloma: Unexpected Intra-clonal Heterogeneity of Copy Number Aberrations in the 1q21-31 Region
36. Can we cure Multiple Myeloma by 2020? Yes
37. Inhibiting MEK in MAPK pathway-activated myeloma
38. Monoclonal gammopathy of undetermined significance: a consensus statement
39. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
40. Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders
41. SURVIVAL EFFECT OF ERYTHOPOIETIC AGENTS AND VENOUS THROMBOEMBOLISM (VTE) IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE AND HIGH-DOSE DEXAMETHASONE
42. Prevention of thalidomide and lenalidomide associated trombosis in myeloma
43. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
44. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma
45. Quantitative bone ultrasound at phalanges and calcaneus in osteoporotic postmenopausal women: influence of age and measurement site
46. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
47. Farnesyltransferase inhibitors and rapamycinin the treatment of multiple myeloma
48. Serum levels of calcitonin in Cushing’s syndrome
49. Unimodal distribution of postmenopausal bone loss after bilateral ophorectomy in adult normal women
50. 341 Targeting NEK2 kinase in drug resistant multiple myeloma with small molecule inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.